Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oxatomide→

Oxatomide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
60607-34-3
Molecular formula
C27H30N4O
Molecular weight
426.6 g/mol
Drug class
Second-generation H1 antihistaminemast-cell stabilising and antiallergic agent
Mechanism of action
Antagonises histamine H1 receptors and inhibits mediator release from mast cells and basophils, including histamine, leukotrienes and prostaglandins. It also inhibits selected calcium-dependent degranulation pathways.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis, chronic urticaria and selected allergic skin disorders in countries where oxatomide is authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/1690009/ · https://pubmed.ncbi.nlm.nih.gov/10513346/ · https://www.caymanchem.com/pdfs/42288.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oxatomide Environmental Risk Assessment (ERA) (the Oxatomide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.